山东地区稳定性冠心病中医证候分布研究

注册号:

Registration number:

ITMCTR2025001309

最近更新日期:

Date of Last Refreshed on:

2025-07-01

注册时间:

Date of Registration:

2025-07-01

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

山东地区稳定性冠心病中医证候分布研究

Public title:

Research on the Distribution of Traditional Chinese Medicine Syndromes for Stable Coronary Heart Disease in Shandong Province

注册题目简写:

English Acronym:

研究课题的正式科学名称:

山东地区稳定性冠心病中医证候分布研究

Scientific title:

Research on the Distribution of Traditional Chinese Medicine Syndromes for Stable Coronary Heart Disease in Shandong Province

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

姜枫

研究负责人:

李运伦

Applicant:

Feng Jiang

Study leader:

Yunlun Li

申请注册联系人电话:

Applicant telephone:

15165078219

研究负责人电话:

Study leader's telephone:

13869102760

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

jiang.maple@163.com

研究负责人电子邮件:

Study leader's E-mail:

li.yunlun@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

山东省济南市文化西路42号山东省中医院

研究负责人通讯地址:

山东省济南市文化西路42号山东省中医院

Applicant address:

No. 42 Wenhua West Road Jinan City Shandong Province Shandong Province China

Study leader's address:

No. 42 Wenhua West Road Jinan City Shandong Province Shandong Province China

申请注册联系人邮政编码:

Applicant postcode:

250000

研究负责人邮政编码:

Study leader's postcode:

250000

申请人所在单位:

山东中医药大学附属医院

Applicant's institution:

Shandong University of Traditional Chinese Medicine Affiliated Hospital

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

(2025)伦审第(099)号-KY

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

山东中医药大学附属医院伦理委员会

Name of the ethic committee:

Ethics Committee of Shandong University of Traditional Chinese Medicine Affiliated Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2025/5/23 0:00:00

伦理委员会联系人:

袁杰

Contact Name of the ethic committee:

Yuan Jie

伦理委员会联系地址:

山东省济南市历下区经十路16369号

Contact Address of the ethic committee:

No. 16369 Jingshi Road Lixia District Jinan City Shandong Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

18668930168

伦理委员会联系人邮箱:

Contact email of the ethic committee:

sdzyethics@163.com

研究实施负责(组长)单位:

山东中医药大学附属医院

Primary sponsor:

Shandong University of Traditional Chinese Medicine Affiliated Hospital

研究实施负责(组长)单位地址:

山东省济南市文化西路42号

Primary sponsor's address:

No. 42 Wenhua West Road Jinan City Shandong Province Shandong Province China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

山东

市(区县):

济南

Country:

China

Province:

Shandong

City:

Jinan

单位(医院):

山东中医药大学附属医院

具体地址:

山东省济南市文化西路42号

Institution
hospital:

Shandong University of Traditional Chinese Medicine Affiliated Hospital

Address:

No. 42 Wenhua West Road Jinan City Shandong Province Shandong Province China

经费或物资来源:

自拟课题

Source(s) of funding:

Self drafted topic

研究疾病:

稳定性冠心病

研究疾病代码:

Target disease:

stable coronary heart disease

Target disease code:

研究类型:

Study type:

观察性研究

Observational study

研究设计:

Study design:

横断面

Cross-sectional

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

中医药论治特色在于辨证论治,即“证”的判读为病证治疗的核心。拟采用横断面研究设计,调查山东地区稳定性冠心病症状、证素及证候的分布情况,分析不同阶段证素及证候演变规律,以指导辨证分型,为临床处方用药提供病机分析依据。

Objectives of Study:

The characteristic of traditional Chinese medicine treatment lies in the differentiation of syndromes that is the interpretation of "syndrome" is the core of disease treatment. We plan to adopt a cross-sectional study design to investigate the distribution of stable coronary heart disease symptoms syndrome elements and syndromes in Shandong region analyze the evolution of syndrome elements and syndromes at different stages in order to guide syndrome differentiation and provide pathological analysis basis for clinical prescription medication.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

(1)符合稳定性冠心病西医诊断标准; (2)符合《冠心病稳定型心绞痛中医诊疗指南》中任何一种冠心病中医证候诊断标准; (3)首诊有中药汤剂处方,服用后感症状较前缓解者; (4)受试者年龄18-75周岁,男女不限; (5)同意并签署知情同意书

Inclusion criteria

(1) Meets the diagnostic criteria for stable coronary heart disease in Western medicine; (2) Meets any of the traditional Chinese medicine diagnostic criteria for coronary heart disease in the "Guidelines for the Diagnosis and Treatment of Stable Angina Pectoris in Coronary Heart Disease"; (3) Patients who have a prescription for traditional Chinese medicine decoction during their first visit and experience relief of symptoms after taking it; (4) The subjects are aged between 18 and 75 years old with no gender restrictions; (5) Agree and sign the informed consent form

排除标准:

(1)因洋地黄药物、心肌肥厚、左束支传导阻滞等导致心电图ST-T改变者。 (2)同时合并以下器官损害或疾病者:合并有严重脑血管病(脑出血、蛛网膜下腔出血、大面积脑梗死);控制不良的糖尿病(空腹血糖>11 mmol/L)或合并肾病、周围神经病变者;失代偿性心力衰竭(NYHA III—IV级)、恶性心律失常反复发作者、控制不良的稳定性心绞痛(控制后收缩压≥180mmHg或舒张压大≥100mmHg);应用心脏起搏器及脑血管疾病发作史在1年内者;呼吸衰竭、慢性肺病伴有呼吸困难者;肾功能不全者(肌酐大于正常值上限,肾小球滤过率(eGFR)<30ml/min/1.73m2);肝功能异常(ALT、AST大于3倍正常值上限);胃肠病变或胃肠手术后有可能影响药物吸收及其他消化系统严重疾病;合并恶性肿瘤、血液系统疾病或其他系统严重或进行性疾病的患者。 (3)研究治疗不全者 (4)妊娠及围产期女性 (5)有精神疾患、不能配合问卷调查者

Exclusion criteria:

(1) Patients with ST-T changes on electrocardiogram caused by digitalis drugs myocardial hypertrophy left bundle branch block etc. (2) Patients with concurrent organ damage or disease: those with severe cerebrovascular disease (cerebral hemorrhage subarachnoid hemorrhage extensive cerebral infarction); Poor control of diabetes (fasting blood glucose>11 mmol/L) or patients with kidney disease and peripheral neuropathy; Decompensated heart failure (NYHA class III-IV) recurrent malignant arrhythmias poorly controlled stable angina (controlled systolic blood pressure ≥ 180mmHg or diastolic blood pressure ≥ 100mmHg); Individuals who have used pacemakers and have a history of cerebrovascular disease within one year; People with respiratory failure chronic lung disease accompanied by breathing difficulties; Individuals with renal insufficiency (creatinine greater than the upper limit of normal glomerular filtration rate (eGFR)<30ml/min/1.73m2); Abnormal liver function (ALT AST greater than 3 times the upper limit of normal); Gastrointestinal lesions or gastrointestinal surgery may affect drug absorption and other serious digestive system diseases; Patients with combined malignant tumors hematological disorders or other serious or progressive systemic diseases. (3) Research on patients with incomplete treatment (4) Pregnant and perinatal women (5) Individuals with mental illnesses who are unable to cooperate with the questionnaire survey

研究实施时间:

Study execute time:

From 2025-07-01

To      2026-12-31

征募观察对象时间:

Recruiting time:

From 2025-07-15

To      2026-12-31

干预措施:

Interventions:

组别:

稳定性冠心病组

样本量:

2388

Group:

Stable coronary heart disease group

Sample size:

干预措施:

中医证候量表积分

干预措施代码:

Intervention:

Integral score of Traditional Chinese Medicine Syndrome Scale

Intervention code:

样本总量 Total sample size : 2388

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

山东

市(区县):

日照

Country:

China

Province:

Shandong

City:

Rizhao

单位(医院):

莒县中医医院

单位级别:

三级甲等

Institution/hospital:

Juxian Traditional Chinese Medicine Hospital

Level of the institution:

Grade III Grade A

国家:

中国

省(直辖市):

山东

市(区县):

济宁

Country:

China

Province:

shandong

City:

Jining

单位(医院):

济宁市中西医结合医院

单位级别:

三级甲等

Institution/hospital:

Jining Integrated Traditional Chinese and Western Medicine Hospital

Level of the institution:

Grade III Grade A

国家:

中国

省(直辖市):

山东

市(区县):

肥城

Country:

China

Province:

Shandong

City:

Feicheng

单位(医院):

肥城市中医医院

单位级别:

三级甲等

Institution/hospital:

Feicheng Traditional Chinese Medicine Hospital

Level of the institution:

Grade III Grade A

国家:

中国

省(直辖市):

山东

市(区县):

临沂

Country:

China

Province:

Shandong

City:

Linyi

单位(医院):

临沂市中医医院

单位级别:

三级甲等

Institution/hospital:

Linyi Traditional Chinese Medicine Hospital

Level of the institution:

Grade III Grade A

国家:

中国

省(直辖市):

山东

市(区县):

聊城

Country:

China

Province:

Shandong

City:

Liaocheng

单位(医院):

聊城市第五人民医院

单位级别:

三级专科

Institution/hospital:

Liaocheng Fifth People's Hospital

Level of the institution:

Third level specialized hospital

国家:

中国

省(直辖市):

山东

市(区县):

济南

Country:

China

Province:

Shandong

City:

Jinan

单位(医院):

广安门医院济南医院

单位级别:

三级甲等

Institution/hospital:

Guang'anmen Hospital Jinan Hospital

Level of the institution:

Grade III Grade A

国家:

中国

省(直辖市):

山东

市(区县):

东营

Country:

China

Province:

Shandong

City:

Dongying

单位(医院):

东营市胜利医院

单位级别:

三级乙等

Institution/hospital:

Dongying Shengli Hospital

Level of the institution:

Grade III Grade B

国家:

中国

省(直辖市):

山东

市(区县):

潍坊

Country:

China

Province:

Shandong

City:

Weifang

单位(医院):

潍坊市中医院

单位级别:

三级甲等

Institution/hospital:

Weifang Traditional Chinese Medicine Hospital

Level of the institution:

Grade III Grade A

国家:

中国

省(直辖市):

山东

市(区县):

淄博市

Country:

China

Province:

Shandong

City:

Zibo

单位(医院):

淄博市中西医结合医院

单位级别:

三级甲等

Institution/hospital:

Zibo Integrated Traditional Chinese and Western Medicine Hospital

Level of the institution:

Grade III Grade A

国家:

中国

省(直辖市):

山东

市(区县):

烟台

Country:

China

Province:

Shandong

City:

Yantai

单位(医院):

烟台市蓬莱中医医院

单位级别:

三级甲等

Institution/hospital:

Yantai Penglai Traditional Chinese Medicine Hospital

Level of the institution:

Grade III Grade A

国家:

中国

省(直辖市):

山东

市(区县):

菏泽

Country:

China

Province:

Shandong

City:

Heze

单位(医院):

菏泽市中医医院

单位级别:

三级甲等

Institution/hospital:

Heze Traditional Chinese Medicine Hospital

Level of the institution:

Grade III Grade A

国家:

中国

省(直辖市):

山东

市(区县):

滨州

Country:

China

Province:

Shandong

City:

Binzhou

单位(医院):

滨州市中医医院

单位级别:

三级甲等

Institution/hospital:

Binzhou Traditional Chinese Medicine Hospital

Level of the institution:

Grade III Grade A

国家:

中国

省(直辖市):

山东

市(区县):

济南

Country:

China

Province:

Shandong

City:

Jinan

单位(医院):

山东中医药大学附属医院

单位级别:

三级甲等

Institution/hospital:

Shandong University of Traditional Chinese Medicine Affiliated Hospital

Level of the institution:

Grade III Grade A

测量指标:

Outcomes:

指标中文名:

疾病临床症状

指标类型:

主要指标

Outcome:

Clinical symptoms of the disease

Type:

Primary indicator

测量时间点:

患者首次接触

测量方法:

量表

Measure time point of outcome:

Patient's first contact time

Measure method:

scale

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 18
Min age years
最大 75
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

本研究采用分层抽样,从不同地区医院的门诊、病房中随机抽取稳定性冠心病患者,为了保证随机抽样的过程能够再现,我们使用SPSS软件根据设定的种子数生成随机序列,根据序列编号对相应诊次的患者进行信息收集

Randomization Procedure (please state who generates the random number sequence and by what method):

This study used stratified sampling to randomly select stable coronary heart disease patients from outpatient clinics and wards of hospitals in different regions. In order to ensure the reproducibility of the random sampling process we used SPSS software to generate a random sequence based on the set seed number and collected information from patients in the corresponding diagnosis based on the sequence number

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

--

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据信息通过各中心填报的CRF表进行采集,由专人录入的稳定性心绞痛患者证型数据调查表中的相关内容录入到Microsoft Excel中,建立数据库,便于后续统计分析。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRFMicrosoft Excel 83/10000 The data information is collected through CRF forms filled out by each center and the relevant content of the stable angina patient syndrome data survey form entered by a dedicated person is entered into Microsoft Excel to establish a database for subsequent statistical analysis.

数据管理委员会:

Data Managemen Committee:

暂未确定

Not yet

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统